RESULTS: There were no differences between AM and IL patients related to gender, sleepiness score, compliance, or perceived benefit at baseline. Prior to ASV initiation, patients in both pathways had elevated residual apnea-hypopnea indices (mean AHI, AM 17.4/h, IL 22.4/h, p=0.041), clinically significant sleepiness scores (means, AM 9.7, IL 10.5, p=0.391) and excellent adherence with APAP therapy (mean percent days used AM 75.3%, IL 80.8%, p=0.325; mean average hours/day used AM 4.9h/d, IL 4.7h/d, p=0.733). Although both AM and IL pathways resulted in an improvement in residual AHI at first follow up, there was no difference between the groups in the overall mean reduction of the AHI (AM -9.6/h, IL -11.9/h, p=0.284). There was no overall change in perceived benefit in patients in either arm (p=0.372), though more patients endorsed feeling subjective benefit in the IL arm at first ASV follow up (p=0.045). There was no difference in sleepiness between AM and IL after ASV (p=0.542).